We are live on
!
Find out more
IHAM
Integral Health Asset Management Portfolio holdings
AUM
$2.09B
1-Year Est. Return
112.84%
This Fund
S&P 500
This Quarter
Est. Return
-1.34%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$348M
AUM Growth
-$15.4M
(-4.2%)
Cap. Flow
+$604K
Cap. Flow
% of AUM
0.17%
Top 10 Holdings %
Top 10 Hldgs %
35.81%
Holding
95
New
24
Increased
19
Reduced
22
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVS Health
CVS
|
+$12.6M |
| 2 |
Pfizer
PFE
|
+$11.1M |
| 3 |
HOLX
Hologic
HOLX
|
+$9M |
| 4 |
APLS
Apellis Pharmaceuticals
APLS
|
+$8.71M |
| 5 |
Lifestance Health
LFST
|
+$6.74M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$12.1M |
| 2 |
Cytokinetics
CYTK
|
+$11M |
| 3 |
Elevance Health
ELV
|
+$9.5M |
| 4 |
Sanofi
SNY
|
+$9.22M |
| 5 |
LHCG
LHC Group LLC
LHCG
|
+$8.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.71% |
| 2 | Energy | 0% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Axogen
AXGN
$2.61B
| – | – |
-70,000
| Closed | -$1.51M |
|
77
BioCryst Pharmaceuticals
BCRX
$2.64B
| – | – |
-125,000
| Closed | -$1.98M |
|
|
78
Biogen
BIIB
$30.1B
| – | – |
-35,000
| Closed | -$12.1M |
|
79
BioNTech
BNTX
$23.3B
| – | – |
-17,000
| Closed | -$3.81M |
|
80
Danaher
DHR
$146B
| – | – |
-16,920
| Closed | -$4.03M |
|
81
iRhythm Holdings
IRTC
$4.02B
| – | – |
-50,000
| Closed | -$3.32M |
|
82
Karyopharm Therapeutics
KPTI
$47.6M
| – | – |
-10,000
| Closed | -$1.55M |
|
83
Seres Therapeutics
MCRB
$46.6M
| – | – |
-3,750
| Closed | -$1.79M |
|
84
Pennant Group
PNTG
$1.33B
| – | – |
-90,000
| Closed | -$3.68M |
|
|
85
Sanofi
SNY
$104B
| – | – |
-175,000
| Closed | -$9.22M |
|
86
Teleflex
TFX
$5.91B
| – | – |
-20,000
| Closed | -$8.04M |
|
87
UnitedHealth
UNH
$361B
| – | – |
-5,000
| Closed | -$2M |
|
88
Zai Lab
ZLAB
$2.92B
| – | – |
-25,000
| Closed | -$4.42M |
|
|
ACCD
89
DELISTED
Accolade Inc
ACCD
| – | – |
-100,000
| Closed | -$5.43M |
|
|
AXNX
90
DELISTED
Axonics, Inc. Common Stock
AXNX
| – | – |
-40,000
| Closed | -$2.54M |
|
|
ONEM
91
DELISTED
1Life Healthcare
ONEM
| – | – |
-50,000
| Closed | -$1.65M |
|
|
LHCG
92
DELISTED
LHC Group LLC
LHCG
| – | – |
-42,000
| Closed | -$8.41M |
|
|
TRIL
93
DELISTED
Trillium Therapeutics Inc.
TRIL
| – | – |
-150,000
| Closed | -$1.46M |
|
|
KDMN
94
DELISTED
Kadmon Holdings, Inc.
KDMN
| – | – |
-225,000
| Closed | -$871K |
|
|
MSON
95
DELISTED
Misonix Inc
MSON
| – | – |
-45,000
| Closed | -$998K |
|
Similar funds
CL
ACM
ACG
NSUP
TP
ACP
TA
AG
Integral Health Asset Management's Q3 2021 Portfolio in Review
As of Q3 2021, Integral Health Asset Management held 95 positions worth $348M, down 4.2% from $363M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Integral Health Asset Management's Q3 2021 filing shows 24 new, 19 increased, 22 reduced and 25 closed positions. Its largest new stake was CVS Health: 150,000 shares worth $12.7M. The largest sale was Biogen, an estimated $12.1M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 93% a quarter earlier, followed by Energy and Industrials.
- Integral Health Asset Management's largest Q3 2021 buy was CVS Health: 150,000 shares worth $12.7M.
- Integral Health Asset Management added most to Apellis Pharmaceuticals in Q3 2021, an estimated $8.71M increase.
- Integral Health Asset Management's biggest Q3 2021 reduction was Cytokinetics, cutting an estimated $11M.
- Integral Health Asset Management fully exited Biogen in Q3 2021, selling an estimated $12.1M.
- Integral Health Asset Management's ten largest holdings make up 36% of its $348M portfolio in Q3 2021.
- Integral Health Asset Management opened 24 new positions and closed 25 in Q3 2021.
- Integral Health Asset Management's portfolio value fell 4.2% quarter-over-quarter to $348M.
Based on Integral Health Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.